CSF hFABP has also been shown to predict progression from MCI to AD [119], correlate with brain atrophy among individuals with low CSF Aβ42 [67], differentiate AD and DLB from Parkinson’s disease (PD) and other neurological diseases [53], and correlate with cognitive impairment in a cohort of patients with different neurodegenerative diseases [53]. The gene discussed is FABP3; the disease is Lewy body dementia.